Loading
A phase 1/2 trial of Pivekimab sunirine in blastic plasmacytoid dendritic cell neoplasm and myeloproliferative neoplasms, run by AbbVie, active and no longer recruiting.
Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN is a phase 1/2 interventional study registered as NCT03386513 by AbbVie, with 179 participants enrolled, started 2018-01-02 and due to reach its primary completion in 2024-10-02. Interventions recorded: IMGN632. Results have been posted on the registry.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
179 enrolled.
95% CI 49.78 to 89.27; Figures from the ClinicalTrials.gov results section (first posted 2026-09-04), not from a publication
Source95% CI 3.943 to 8.378; Figures from the ClinicalTrials.gov results section (first posted 2026-09-04), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Composite Complete Remission/Response (CCR) Rate As Assessed by Investigator in Frontline De Novo Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Participantsprimary | Frontline De Novo BPDCN Participants - Schedule A: IMGN632 0.045 mg/kg | 22 | 72.7% | - | - | link |
| Overall Survival in Total R/R BPDCN Participants | Total R/R BPDCN Participants - Schedule A: IMGN632 0.045 mg/kg | 51 | 5.78 months | - | - | link |
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pivekimab sunirine, AbbVie (incl. ImmunoGen, Capstan), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Pivekimab sunirine, AbbVie (incl. ImmunoGen, Capstan), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares AbbVie (incl. ImmunoGen, Capstan), Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares AbbVie (incl. ImmunoGen, Capstan) and the tag pipeline.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares AbbVie (incl. ImmunoGen, Capstan) and the tag pipeline.
Shares AbbVie (incl. ImmunoGen, Capstan) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/